HealthInvest returns to Sydney, highlighting emerging ASX healthcare talent

• Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on September 24
• This event will highlight some of ASX’s leading up-and-coming health and life sciences companies
• Clever Culture Systems, Cogstate, EBR Systems, Neurizon Therapeutics and Tetratherix will all present

Stockhead, in partnership with investor relations firm IR Department and broker Morgans, will host its second HealthInvest 2025 event in Sydney, on September 24, showcasing emerging ASX-listed healthcare companies to potential investors. 

The event will profile some of the ASX’s leading and up-and-coming health and life sciences players, giving both professional and retail investors the chance to hear directly from company executives.

Networking will follow, accompanied by drinks and canapés.

Among the companies presenting are:

Clever Culture Systems (ASX:CCS)

Based in Adelaide Clever Culture systems have developed the Automated Plate Assessment System (APAS Independence), using artificial intelligence (AI) and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates.

The technology is the only US Food and Drug Administration (FDA) cleared AI technology for automated culture plate reading.

The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates.

Investors will hear directly from CEO and managing director Brent Barnes, who has headed the company since 2016 and has skin in the game as a major shareholder.

Barnes has led the successful transition of its flagship AI and machine vision technology APAS, from invention to commercialisation.

He previously spent 11 years at Cochlear Limited (ASX:COH) as a senior executive, overseeing a broad range of global operational and strategic functions.

Cogstate (ASX:CGS)

The neuroscience technology company focused on optimising brain health assessments to advance new medicines and enable earlier clinical insights in healthcare.

Cogstate’s tech delivers rapid, reliable and highly sensitive computerised cognitive tests across a growing range of domains.

It also supports partners with electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper-based assessments with real-time digital data capture.

Cogstate’s clinical trial services combine innovative operational models, advanced analytics and scientific consulting to ensure quality assurance of study endpoints.

For more than 20 years, the company has supported biopharmaceutical companies, academic institutions, physicians and patients worldwide.

Presenting will be CEO and managing director Brad O’Connor, who has led the company since 2005, driving its rise as a global leader in digital cognitive assessment for clinical trials and healthcare.

Under his leadership, Cogstate delivered record FY25 revenue of US$53.1 million, strong profit growth and declared its first dividend.

O’Connor’s focus on scalability, operational excellence and strategic partnerships has helped secure Cogstate a leading role in CNS research, including pivotal Alzheimer’s and neuroscience trials.

EBR Systems (ASX:EBR)

The Silicon Valley-based medical device company is focused on improving the treatment of cardiac rhythm disease through its proprietary Wireless Stimulation Endocardially (WiSE) technology.

WiSE technology is the world’s only wireless, endocardial pacing system in clinical use for stimulating the left ventricle and was approved by the FDA in April.

By eliminating the need for cardiac pacing leads, historically a major source of complications, WiSE offers a potentially safer and more physiologically effective solution for patients requiring Cardiac Resynchronisation Therapy (CRT).

The company’s pipeline also targets bradycardia and other indications, broadening future growth opportunities.

President and CEO John McCutcheon will make the EBR presentation. With more than 40 years of leadership in medical devices, McCutcheon has overseen multiple start-ups through acquisition and served on the boards of several high-growth companies.

His extensive track record in sales, marketing and general management gives him the perfect background to successfully drive EBR’s global growth strategy.

Neurizon Therapeutics (ASX: NUZ)

This clinical-stage biotech is advancing new treatments for neurodegenerative diseases. Neurizon’s lead candidate NUZ-001 is in development for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease.

Neurizon’s strategy is to accelerate access to effective ALS therapies while assessing NUZ-001’s potential in other neurodegenerative disorders.

Through international collaborations and rigorous clinical programs, Neurizon is working to create new options for patients and families impacted by complex neural conditions.

CEO and managing director Dr Michael Thurn will provide the Neurizon overview at the event.

The experienced exec has led multiple US FDA investigational new drug (IND) applications across a range of therapeutic areas, as well as evaluating drugs and vaccines for the Therapeutic Goods Administration (TGA).

He has also overseen the execution of clinical trials and managed business development activities.

Thurn brings strong entrepreneurial, leadership and management skills, developed over a 25-year career in the biotechnology industry, consistently helping to deliver strong results.

Tetratherix (ASX:TTX)

New kid on the block Tetratherix made its ASX debut on June 30 and is pioneering advanced biomaterial solutions to transform treatment of complex diseases.

Its proprietary polymer platform enables the targeted delivery of cells, drugs and biologics, with applications spanning oncology, regenerative medicine and beyond.

With a mission to deliver scalable, global impact, Tetratherix combines scientific innovation with a collaborative business model designed to integrate with healthcare systems and partners worldwide.

CEO and executive director Will Knox will jump on the mic. Knox has a strong background in commercialising biomedical innovations, including the successful acquisition of a company he founded in 2013.

At Tetratherix, he is positioning the company as a next-generation biomedical platform with global ambitions.

HealthInvest 2025 will run from 4.45pm to 7pm with doors open 4.15pm at Morgans, Level 21, 88 Phillip Street, Sydney. Tickets are free and available via the event website.

At Stockhead, we tell it like it is. While Clever Culture Systems, EBR Systems and Neurizon Therapeutics are Stockhead advertisers, the companies did not sponsor this article.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.